← back to search

Shoaib Ugradar

IS practice ·
Area of research
Pathology and Forensic Medicine · Ophthalmology
Research interest
Research interests include Ophthalmology and Eye Disorders, Facial Rejuvenation and Surgery Techniques, Glaucoma and retinal disorders, and Ocular Diseases and Behçet’s Syndrome.
h-index
20
citations
1,383
works
93
NIH funding
primary concept
email

Recent publications

The Rate of Re-treatment in Patients Treated with Teprotumumab
Ophthalmology 2024cited by 17position: firstdoi
Surgical Timing for Patients With Thyroid Eye Disease Treated With Teprotumumab: A Collaborative Multicenter Study
Ophthalmic Plastic and Reconstructive Surgery 2024cited by 7position: middledoi
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
The Journal of Clinical Endocrinology & Metabolism 2023cited by 67position: middledoi
Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease
Ophthalmic Plastic and Reconstructive Surgery 2023cited by 17position: middledoi
The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial
Journal of Plastic Reconstructive & Aesthetic Surgery 2023cited by 11position: middledoi
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease
JAMA Ophthalmology 2022cited by 60position: middledoi
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment
Ophthalmology 2021cited by 154position: middledoi
Teprotumumab for the treatment of chronic thyroid eye disease
Eye 2021cited by 94position: firstdoi
Increased incidence of chalazion associated with face mask wear during the COVID-19 pandemic
American Journal of Ophthalmology Case Reports 2021cited by 44position: lastdoi
Improvement of asymmetric thyroid eye disease with teprotumumab
British Journal of Ophthalmology 2021cited by 19position: firstdoi
Teprotumumab for thyroid eye disease: early response is not required for benefit
Eye 2021cited by 7position: firstdoi
Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease
British Journal of Ophthalmology 2020cited by 66position: middledoi
In Vivo Measurement of the Human Vitreous Chamber Volume Using Computed Tomography Imaging of 100 Eyes
Translational Vision Science & Technology 2020cited by 58position: lastdoi
Differential Regional Stiffening of Sclera by Collagen Cross-linking
Current Eye Research 2019cited by 27position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Raymond S. Douglas · Thrive10 papers (2020–2024)Sara T. Wester · University of Miami5 papers (2021–2024)George J. Kahaly · Johannes Gutenberg University Mainz4 papers (2020–2021)Kevin D. Clauss · University of Miami3 papers (2023–2024)Andrea L. Kossler · Smith-Kettlewell Eye Research Institute3 papers (2021–2024)Wendy W. Lee · University of Miami2 papers (2023–2023)Hannah Walsh · University of Miami2 papers (2024–2024) · 2 papers (2024–2024)Suzanne K. Freitag · Boston Medical Center2 papers (2024–2024)Kimberly Cockerham · University of San Diego2 papers (2021–2023)Prem S. Subramanian · University of Colorado Denver2 papers (2022–2023)Carolina A. Chiou · Brown University2 papers (2024–2024)Rosa A. Tang · Eye Center2 papers (2021–2023)Roger A. Dailey · Legacy Health2 papers (2021–2022)Brian Fowler · University of Idaho2 papers (2021–2023) · 2 papers (2020–2021)Tünde Mester · University of Massachusetts Amherst2 papers (2021–2021)Kambiz Ameli · University of Miami1 papers (2023–2023)Kate Hsu · Amgen (United States)1 papers (2023–2023)Ada Kumar · Amgen (United States)1 papers (2020–2020)